Transcatheter aortic-valve replacement for inoperable severe aortic stenosis.
Publication/Presentation Date
5-3-2012
Abstract
BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates for surgery. The outcomes beyond 1 year in such patients are not known.
METHODS: We randomly assigned patients to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty). Data on 2-year outcomes were analyzed.
RESULTS: A total of 358 patients underwent randomization at 21 centers. The rates of death at 2 years were 43.3% in the TAVR group and 68.0% in the standard-therapy group (P
CONCLUSIONS: Among appropriately selected patients with severe aortic stenosis who were not suitable candidates for surgery, TAVR reduced the rates of death and hospitalization, with a decrease in symptoms and an improvement in valve hemodynamics that were sustained at 2 years of follow-up. The presence of extensive coexisting conditions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
Volume
366
Issue
18
First Page
1696
Last Page
1704
ISSN
1533-4406
Published In/Presented At
Makkar, R. R., Fontana, G. P., Jilaihawi, H., Kapadia, S., Pichard, A. D., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Webb, J. G., Herrmann, H. C., Bavaria, J. E., Kodali, S., Brown, D. L., Bowers, B., Dewey, T. M., Svensson, L. G., Tuzcu, M., Moses, J. W., Williams, M. R., Siegel, R. J., … PARTNER Trial Investigators (2012). Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. The New England journal of medicine, 366(18), 1696–1704. https://doi.org/10.1056/NEJMoa1202277
Disciplines
Medicine and Health Sciences
PubMedID
22443478
Department(s)
Department of Surgery
Document Type
Article